Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 12
Semaglutide below max dose: real-world data
A Slovak observational study found 11.35% mean weight loss at six months on submaximal semaglutide doses. Below trial figures, but clinically relevant.
Who loses less weight on semaglutide?
A 163-patient retrospective study links diabetes, age over 60, and Hispanic ethnicity to lower weight loss on semaglutide at 12 months.
Most statin label warnings lack evidence
A 2026 Lancet meta-analysis found only 4 of 66 listed statin side effects are backed by trial evidence. What GLP-1 users should know.
Greener route to tirzepatide synthesis
A 2026 JACS study combines tag-assisted synthesis with selenoester ligation to assemble peptide drugs up to 39 residues long using far less solvent.
TB-500 and Flexibility: What We Know
Community users report flexibility gains on TB-500. The preclinical mechanism is plausible, but no human study has measured it. Here is the full picture.
Tirzepatide and metformin for PCOS: RCT
A 60-patient Chinese trial found tirzepatide 5 mg plus metformin cut weight by 10.4 kg in 16 weeks for women with PCOS, six times more than metformin alone.
TOGETHER-PsA: tirzepatide plus ixekizumab
A Phase 3b trial finds that adding tirzepatide to ixekizumab improves joint disease and weight in psoriatic arthritis patients with obesity.
GLP-1 drugs in teens: what youth say
A qualitative study of 29 adolescents on GLP-1 and other weight-loss drugs finds families are positive about treatment but uncertain about when to stop.
Peptide blood work: which labs to request
IGF-1, fasting glucose, HbA1c, lipid panel, CMP, CBC, and thyroid markers. Here is what each one tracks and why your clinician may want it.
Why patients stop GLP-1 drugs, and restart
A narrative review in Diabetes, Obesity & Metabolism examines GLP-1 RA discontinuation rates, reasons, and weight-regain patterns after stopping.
GLP-1 drugs and severe GI motility risk
A 626,000-person cohort study found GLP-1 therapies carry a 37% higher relative risk of severe GI events versus SGLT-2 inhibitors.
Tirzepatide and ketoacidosis: FAERS signal
A FAERS analysis flags starvation ketoacidosis as a post-marketing signal for tirzepatide. Here is what the numbers say.